Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Government Rejects WHO Definition Of Counterfeit Drugs; Stresses Need For Harmonization Among Member States

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Indian government may have succeeded in blocking a move to redefine "counterfeit drugs" by the International Medical Products Anti-Counterfeiting Taskforce - an arm of the World Health Organization. In its definition, IMPACT defined a medical product as counterfeit "when there is a false representation in relation to its identity, history or source.
Advertisement

Related Content

India Says Counterfeit Drugs Should Be Handled By WTO - Not WHO
India Says Counterfeit Drugs Should Be Handled By WTO - Not WHO
Roche India's Efforts To Curb Fake Drugs Gain Popularity
Roche India's Efforts To Curb Fake Drugs Gain Popularity
Advertisement
UsernamePublicRestriction

Register

SC069369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel